Almost ten years after the first funding round by founding father and shareholder UTIV, U-Needle announces completion of a second funding round as part of the management buy-in by Dr. Gert Veldhuis and Mr. Jeroen Wissink, who will jointly form the U-needle’s new Board of Directors as of January 15, 2018.

U-Needle expects CE approval of U-Needle’s first microneedle product Bella-mu in February 2018. Anticipating this approval, the 0.5 million EUR capital injection will be used to accelerate the company’s growth strategy and enter new application markets.

To this end, U-Needle will shift her focus from microneedle research and development towards the development of clinical applications of Bella-mu and related products in the field of aesthetics, vaccination and diabetes.

 

U-Needle

U-Needle develops proprietary microneedle technology applied in various user-friendly intradermal injection devices for aesthetics, vaccination and diabetes therapies.

The advanced microneedle technology facilitates fast therapy onset and reduced dose in pharmaceutical injectables.

 

 

 

Capital injection for accelerated growth

Leave a Reply

Your email address will not be published. Required fields are marked *